SUPERSTRING CAPITAL MANAGEMENT LP
Position in QNCX — Quince Therapeutics, Inc.
CIK 1931118
NEW YORK, NY
Position in QNCX
as of Dec 31, 2025
· filed Feb 17, 2026
Position Value
$575,336,370
New position
Shares Held
858,711
first reported quarter
Ownership
5.27%
of shares outstanding
% of Portfolio
79.23%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026SUPERSTRING CAPITAL MANAGEMENT LP holds $130,439,416 across 32 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SMMT |
Summit Therapeutics Inc.
|
892,873 | $16,928,872 | |
| 2 | IMVT |
Immunovant, Inc.
|
357,606 | $8,882,933 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
225,158 | $8,666,331 | |
| 4 | SVRA |
Savara Inc
|
1,585,977 | $8,659,434 | |
| 5 | URGN |
UroGen Pharma Ltd.
|
387,371 | $6,964,930 | |
| 6 | DFTX |
Definium Therapeutics, Inc.
|
351,461 | $6,642,612 | |
| 7 | VIR |
Vir Biotechnology, Inc.
|
730,548 | $6,545,710 | |
| 8 | PCVX |
Vaxcyte, Inc.
|
110,454 | $6,418,481 |
All Filings in QNCX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2025-12-31 | $575,336,370 | 858,711 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||